A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease.
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Valsartan (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 19 Apr 2016 Primary end points has been modified
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Apr 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.